According to filings with the U.S. Securities and Exchange Commission, Kriya Therapeutics is raising up to $313,297,440.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Kriya Therapeutics
Our mission is to revolutionize medicine, with the ultimate goal of eliminating human suffering and enabling people to live without the burden of disease. Kriya is a biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world. With operations in Research Triangle Park, North Carolina, and Palo Alto, California, Kriya has raised over $600 million to advance a broad pipeline of gene therapies in ophthalmology, metabolic disease and neurology.

To learn more about Kriya Therapeutics, visit https://kriyatherapeutics.com/
Kriya Therapeutics Linkedin Page: https://www.linkedin.com/company/kriyatx/

Contact:
Shankar Ramaswamy, Chief Executive Officer
833-574-9289
https://www.linkedin.com/in/shankar-ramaswamy-m-d-8334959/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.